Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05826353 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
A Phase 3 study, sponsored by Kowa Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
NCT05826353 is a Phase 3 study that has completed, run by Kowa Research Institute. The registered enrollment target is 110 participants.
The verdict
NCT05826353, a Phase 3 study, has completed, sponsored by Kowa Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
Study Summary
A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.
Interventions
- DRUG Placebo
- DRUG Ripasudil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2023-05-11 |
| Est. Completion | 2025-10-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05826353
The ClinicalTrials.gov registry entry for NCT05826353 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kowa Research Institute, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05826353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05826353 about?
NCT05826353 is a clinical study titled "A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)". A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.
What is the current status of trial NCT05826353?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2023-05-11. Estimated completion is 2025-10-24.
What interventions are being tested in trial NCT05826353?
The interventions under investigation include: Placebo (DRUG), Ripasudil (DRUG).
Who is sponsoring clinical trial NCT05826353?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.